TA-CIN Vaccine With Anti-PD-1 Therapy in Recurrent HPV16-associated Cancers

Summary

The primary to assess the safety and tolerability of TA-CIN and anti-PD-1 therapy in patients with recurrent HPV16-associated cancers and to assess the feasibility of IT injection of TA-CIN in patients with recurrent HPV16-associated cancers undergoing treatment with anti-PD-1 therapy.

Timeline

Start

2021-08

Primary completion

2022-01-18

Completion

2022-01-18

Outcome

Outcome not reported

Stopped: “The study team decided not to move forward with the study.”

Drugs

Indications